RTP Mobile Logo
Cases from the Community: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer (Webinar Video Proceedings)
Released May 2022

Featuring perspectives from Drs Matthew Galsky, Ashish Kamat and Stephen Williams, moderated by Dr Sumanta Kumar Pal. Published May 25, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.


    • Consider data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into patient care.
    • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and understand the current role of this strategy.
    • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder carcinoma (UBC).
    • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy for newly diagnosed metastatic UBC, and recognize the utility of these agents in practice.
    • Recall pivotal trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and discuss with patients why these agents would be appropriate.
    • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
    • Develop an understanding of the biologic rationale for, research findings with and ongoing studies evaluating promising agents and strategies for NMIBC, MIBC and metastatic UBC.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUA22Bladder/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY & MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:


    Matthew D Galsky, MD
    Professor of Medicine
    Icahn School of Medicine at Mount Sinai
    Co-Leader, Bladder Cancer Center of Excellence
    Associate Director, Translational Research
    The Tisch Cancer Institute
    New York, New York

    Advisory Committee: Aileron Therapeutics Inc, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, BioMotiv, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Dracen Pharmaceuticals, Dragonfly Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Numab, Pfizer Inc, Seagen Inc, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.

    Ashish M Kamat, MD, MBBS
    Professor of Urologic Oncology (Surgery)
    Wayne B Duddlesten Professor of Cancer Research
    Department of Urology, Division of Surgery
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No relevant conflicts of interest to disclose.

    Stephen B Williams, MD, MS
    Medical Director, High Value Care
    UTMB Health System
    Chief, Division of Urology
    Professor (Tenured), Urology and Radiology
    Robert Earl Cone Professorship
    Director of Urologic Oncology
    Director of Urologic Research
    Co-Director of the Surgical Outcomes Research Division
    The University of Texas Medical Branch
    Galveston, Texas

    No relevant conflicts of interest to disclose.


    Sumanta Kumar Pal, MD
    Professor, Department of Medical Oncology and Therapeutics Research
    City of Hope
    Duarte, California

    No relevant conflicts of interest to disclose.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: May 2022
    Expiration date: May 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):